People · Operator
Named in public records as an officer, director or promoter · active 2017–2020 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Rapamycin Holdings, Inc. | — | Pharmaceuticals | Series A | $17.9M | $216.8M | 2017 |
| StemBioSys Inc. | — | Biotechnology | Series A | $9.9M | $43.8M | 2019 |
Mark Horsey at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Horsey on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Langer | 1 | 36 |
| Robert S Langer | 1 | 14 |
| Steven Davis | 1 | 6 |
| Paul Castella | 1 | 6 |
| John Feik | 1 | 2 |
| Jean Cheever | 1 | 2 |
| Peter Savas | 1 | 2 |
| Chen W Xiao-Dong | 1 | 1 |
| Ian W Clements | 1 | 1 |
| Catherine W Burzik | 1 | 1 |
| Jean W Cheever | 1 | 1 |
| Robert D Hutchens | 1 | 1 |
| Mark D Horsey | 1 | 1 |
| Mark H Horsey | 1 | 1 |
| Randy H Goldsmith | 1 | 1 |
| Stephen H Dufilho | 1 | 1 |
| Becky Cap | 1 | 1 |
| Xiao-Dong W Chen | 1 | 1 |
| Robert Hutchens | 1 | 1 |
| Xiao-Dong Chen | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.